NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free ESPR Stock Alerts $2.68 +0.06 (+2.29%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.54▼$2.8050-Day Range$2.02▼$2.9052-Week Range$0.70▼$3.34Volume8.18 million shsAverage Volume6.25 million shsMarket Capitalization$495.93 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Esperion Therapeutics alerts: Email Address Esperion Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside248.3% Upside$9.33 Price TargetShort InterestBearish10.48% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment0.33Based on 29 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.75 out of 5 starsMedical Sector276th out of 938 stocksPharmaceutical Preparations Industry130th out of 432 stocks 3.2 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.33, Esperion Therapeutics has a forecasted upside of 248.3% from its current price of $2.68.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.48% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Esperion Therapeutics has recently increased by 4.25%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 3.0 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search Interest34 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.MarketBeat Follows26 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.60% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.61) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Esperion Therapeutics Stock (NASDAQ:ESPR)Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) to Post FY2026 Earnings of $2.50 Per Share, HC Wainwright ForecastsMarch 26, 2024 | finance.yahoo.comEsperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceMarch 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 26, 2024 | americanbankingnews.comEsperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at Needham & Company LLCMarch 26, 2024 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Earns "Buy" Rating from HC WainwrightMarch 26, 2024 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Hold" by BrokeragesMarch 26, 2024 | americanbankingnews.comStock Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)March 26, 2024 | msn.comWhy Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?March 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 25, 2024 | globenewswire.comEsperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24March 25, 2024 | msn.comEsperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market SessionMarch 23, 2024 | money.usnews.comEsperion Therapeutics Inc.March 22, 2024 | finance.yahoo.comU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | businesswire.comU.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | globenewswire.comU.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseMarch 22, 2024 | marketwatch.comEsperion Therapeutics Gets CHMP Positive Opinion for Cholesterol MedicationsMarch 22, 2024 | globenewswire.comCHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsMarch 22, 2024 | americanbankingnews.comZacks Research Analysts Cut Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)March 21, 2024 | americanbankingnews.comAnalysts Offer Predictions for Esperion Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ESPR)March 14, 2024 | msn.comTerns to report Phase 1 data on GLP-1 drug in 2H 2024March 4, 2024 | finance.yahoo.com11 Best Small Cap Pharma Stocks to Invest InFebruary 28, 2024 | seekingalpha.comA Relief Earnings Report Ahead Of An Inflection Point For Esperion TherapeuticsFebruary 28, 2024 | finance.yahoo.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 Esperion Therapeutics Inc Earnings CallFebruary 27, 2024 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | finance.yahoo.comEsperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023February 27, 2024 | globenewswire.comEsperion Reports Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+248.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-179.87% Pretax Margin-179.87% Return on EquityN/A Return on Assets-91.62% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio0.87 Sales & Book Value Annual Sales$116.33 million Price / Sales4.26 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.70Miscellaneous Outstanding Shares185,050,000Free Float183,943,000Market Cap$495.93 million OptionableOptionable Beta0.82 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Sheldon L. Koenig (Age 58)President, CEO & Director Comp: $1.2MMr. Benjamin O. Looker (Age 42)General Counsel Comp: $550.35kDr. JoAnne Micale Foody FACC (Age 58)M.D., Chief Medical Officer Comp: $771.19kMr. Benjamin Halladay M.B.A. (Age 38)Chief Financial Officer Mr. Glenn P. Brame (Age 66)Chief Technical Operations Officer Tiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsMs. Betty Jean SwartzChief Business OfficerMr. Eric J. Warren R.Ph. (Age 52)Chief Commercial Officer More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELRevance TherapeuticsNASDAQ:RVNCNkartaNASDAQ:NKTXIGM BiosciencesNASDAQ:IGMSLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Sold 78,676 shares on 3/27/2024Ownership: 0.020%Vanguard Group Inc.Bought 396,388 shares on 3/11/2024Ownership: 2.776%Goldman Sachs Group Inc.Sold 119,595 shares on 3/1/2024Ownership: 0.930%Chicago Partners Investment Group LLCSold 14,433 shares on 2/23/2024Ownership: 0.013%GSA Capital Partners LLPBought 11,494 shares on 2/16/2024Ownership: 0.992%View All Insider TransactionsView All Institutional Transactions ESPR Stock Analysis - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued 1-year target prices for Esperion Therapeutics' shares. Their ESPR share price targets range from $4.00 to $16.00. On average, they predict the company's share price to reach $9.33 in the next twelve months. This suggests a possible upside of 248.3% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2024? Esperion Therapeutics' stock was trading at $2.99 at the beginning of 2024. Since then, ESPR stock has decreased by 10.4% and is now trading at $2.68. View the best growth stocks for 2024 here. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.03. The biopharmaceutical company earned $32.25 million during the quarter, compared to analysts' expectations of $26.84 million. During the same period in the previous year, the firm earned ($0.76) EPS. What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Wasatch Advisors LP (7.82%), Vanguard Group Inc. (4.52%), Vanguard Group Inc. (2.78%), Armistice Capital LLC (2.81%), Platinum Investment Management Ltd. (2.47%) and Parkman Healthcare Partners LLC (1.25%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ESPR) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.